Holen Sie sich die Stockscreener-App
28.61
1.38%
-0.40
Handel nachbörslich:
28.61
Schlusskurs vom Vortag:
$29.01
Offen:
$28.88
24-Stunden-Volumen:
6,985
Relative Volume:
0.58
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-2.89%
1M Leistung:
-6.44%
6M Leistung:
-13.64%
1J Leistung:
-13.64%
1-Tages-Spanne:
$28.51
$28.88
1-Wochen-Bereich:
$28.51
$29.53
52-Wochen-Spanne:
$28.51
$36.03
Tema Etf Trust Tema Obesity Cardiometabolic Etf Stock (HRTS) Company Profile
Firmenname
Tema Etf Trust Tema Obesity Cardiometabolic Etf
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie HRTS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRTS
Tema Etf Trust Tema Obesity Cardiometabolic Etf
|
28.61 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
263.96 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
536.70 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
540.07 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
210.85 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
450.66 | 124.43B | 0 | 0 | 0 | 0.00 |
Tema Etf Trust Tema Obesity Cardiometabolic Etf Aktie (HRTS) Neueste Nachrichten
Short Interest in Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Declines By 28.6% - Defense World
7 Best-Performing Biotech ETFs for March 2025 - NerdWallet
Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Short Interest Down 60.0% in February - Defense World
Disruptive Theme of the Week: 2024's Top Investment Themes & Trends - ETF Trends
Reshoring ETF Gets Boost From Trump Trade - etf.com
Tema's New VOLT ETF Sparked by AI Revolution - etf.com
Disruptive Theme of the Week: Happy Post-Election Themes - ETF Trends
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win - Yahoo Finance
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
Tap the Weight-Loss Drug Market With These ETFs - Nasdaq
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says - CNBC
Disruptive Theme of the Week: The Rise of Active Thematic ETFs - ETF Trends
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment - Yahoo Finance
ETF Innovators: 11 people disrupting the industry, creating unique products, and delivering mammoth returns - Business Insider
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO - Markets Insider
This ETF is trying to satisfy appetites for weight loss stocks - CNBC
ETF IQ: Mutual Fund Managers Have the Luxury to Just Say ‘No’ - Bloomberg.com
Weight-loss drug forecasts jump to $150 billion as supply grows - The Business Standard
Watch Looking at Next Gen of Weight Loss: Tema ETFs CEO - Bloomberg
OZEM, Weight Loss Drug ETFs: Should You Invest? - etf.com
Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters - BioSpace
Play These New ETFs to Tap Lucrative Weight Loss Drug Market - Yahoo Finance
Another thematic ETF launches to target global obesity battle - InvestmentNews
S&P 500: April Selloff Could Be a Very Good Thing for the Months Ahead - Investing.com
IBD Stock Of The Day Pops After Obesity Drug Crushes Sales Views - Investor's Business Daily
The 5 Best Biotech ETFs of 2024 - etf.com
This weight-loss ETF has performed well. Here’s a look at other options. - MarketWatch
Is the global battle against obesity an opportunity for investors? - InvestmentNews
First Weight Loss ETF from Tema ETFs Announces Name Change, Tops $50 Million AUM - Markets Insider
Be Thankful — It Could Have Been So Much Worse - Bloomberg
Finanzdaten der Tema Etf Trust Tema Obesity Cardiometabolic Etf-Aktie (HRTS)
Es liegen keine Finanzdaten für Tema Etf Trust Tema Obesity Cardiometabolic Etf (HRTS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.72%
Kapitalisierung:
|
Volumen (24h):